Reactions 1459 - 6 Jul 2013 Erlotinib Rash: case report A 44-year-old man developed a rash while receiving erlotinib. The man had been diagnosed with grade 3 lung adenocarcinoma following presentation in December 2001. He received a number of treatment drugs, including gemcitabine during the period September 2002-December 2002. He completed four cycles of gemcitabine without adverse events, but after the drug was restarted in December 2003 he developed an allergic reaction and gemcitabine was switched to docetaxel in January 2004. He subsequently received gefitinib from July 2004 until August 2007, when it was switched to erlotinib [dosage and route not stated]. He developed a grade 2 rash within 1 month of starting the drug. The man received antibacterials, but the rash persisted. After 2 years of erlotinib, the rash was downgraded to grade 1. He continued to receive erlotinib for more than 5 years and was still receiving the drug at last follow-up. Author comment: "In our patient, grade 2 rash developed after commencing erlotinib treatment. The rash persisted throughout the treatment period, but it was downgraded to grade 1 rash after 2 years." Polychronidou G, et al. Long-term treatment with erlotinib for EGFR wild-type non-small cell lung cancer: A case report. Case Reports in Oncology 6: 189-196, No. 1, Apr 2013. Available from: URL: http://dx.doi.org/10.1159/000350680 - Greece 803089465 1 Reactions 6 Jul 2013 No. 1459 0114-9954/10/1459-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Erlotinib

Download PDF Report

Upload
katsuhiro
View
215
Download
1

Embed Size (px)

Citation preview

Reactions 1459 - 6 Jul 2013

Erlotinib

Rash: case reportA 44-year-old man developed a rash while receiving

erlotinib.The man had been diagnosed with grade 3 lung

adenocarcinoma following presentation in December 2001.He received a number of treatment drugs, includinggemcitabine during the periodSeptember 2002-December 2002. He completed four cyclesof gemcitabine without adverse events, but after the drug wasrestarted in December 2003 he developed an allergic reactionand gemcitabine was switched to docetaxel in January 2004.He subsequently received gefitinib from July 2004 untilAugust 2007, when it was switched to erlotinib [dosage androute not stated]. He developed a grade 2 rash within 1 monthof starting the drug.

The man received antibacterials, but the rash persisted. After2 years of erlotinib, the rash was downgraded to grade 1. Hecontinued to receive erlotinib for more than 5 years and wasstill receiving the drug at last follow-up.

Author comment: "In our patient, grade 2 rash developedafter commencing erlotinib treatment. The rash persistedthroughout the treatment period, but it was downgraded tograde 1 rash after 2 years."Polychronidou G, et al. Long-term treatment with erlotinib for EGFR wild-typenon-small cell lung cancer: A case report. Case Reports in Oncology 6: 189-196,No. 1, Apr 2013. Available from: URL: http://dx.doi.org/10.1159/000350680 -Greece 803089465